SCHEMBL1640585

SCHEMBL1640585

O=c1cnn(-c2cc(Cl)c(Oc3ccc(O)c(S(=O)(=O)NC4CCCCC4)c3)c(Cl)c2)c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 20/20 1.00
THRA P10827 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6215159 0.97 THRB (1.00) THRBTHRA
SCHEMBL6216094 0.96 THRB (0.93) THRBTHRA
SCHEMBL6212949 0.95 THRB (0.91) THRBTHRA
SCHEMBL6218933 0.92 THRB (0.86) THRBTHRA
SCHEMBL6217209 0.88 THRB (0.79) THRBTHRA
SCHEMBL6216637 0.88 THRB (0.78) THRBTHRA
SCHEMBL6286974 0.87 THRB (0.78) THRBTHRA
SCHEMBL6217902 0.87 THRB (0.78) THRBTHRA
SCHEMBL6218456 0.85 THRB (0.74) THRBTHRA
SCHEMBL6218620 0.85 THRB (0.75) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 US claimed
US-20080125433-A1 Method of treating hair loss using thyromimetic compounds CORNELIUS PETER 2008-05-29 US claimed
EP-1262177-B1 Medical use of thyromimetic compounds to treat hair loss and compositions PFIZER PROD INC (US) 2006-08-23 EP claimed
US-6787652-B1 LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES PFIZER, INC. 2004-09-07 US claimed
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands DOW ROBERT L (US) 2004-08-12 US claimed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 WO claimed
US-20030007941-A1 Method of treating hair loss using thyromimetic compounds CORNELIUS PETER (US) 2003-01-09 US claimed
EP-1262177-A2 Medical use of thyromimetic compounds to treat hair loss and compositions Pfizer Products Inc. (US) 2002-12-04 EP claimed
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds DOHERTY NIALL S 2011-04-28 US disclosed
US-20080125433-A1 Method of treating hair loss using thyromimetic compounds CORNELIUS PETER 2008-05-29 US disclosed
EP-1262177-B1 Medical use of thyromimetic compounds to treat hair loss and compositions PFIZER PROD INC (US) 2006-08-23 EP disclosed
US-6930107-B2 6-azauracil derivatives as thyroid receptor ligands PFIZER INC. (US) 2005-08-16 US disclosed
EP-1088819-B1 6-azauracil derivatives as thyroid receptor ligands PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6787652-B1 LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES PFIZER, INC. 2004-09-07 US disclosed
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands DOW ROBERT L (US) 2004-08-12 US disclosed
WO-2004047827-A1 METHOD FOR PROMOTING NAIL GROWTH USING THYROMIMETIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed
US-20030007941-A1 Method of treating hair loss using thyromimetic compounds CORNELIUS PETER (US) 2003-01-09 US disclosed
EP-1262177-A2 Medical use of thyromimetic compounds to treat hair loss and compositions Pfizer Products Inc. (US) 2002-12-04 EP disclosed
EP-1088819-A2 6-azauracil derivatives as thyroid receptor ligands Pfizer Products Inc. (US) 2001-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125433-A1 Method of treating hair loss using thyromimetic compounds TRHDE, TPO, THRB THRB 3/4885THRA 4/4885
US-20030007941-A1 Method of treating hair loss using thyromimetic compounds TRHDE, TPO, THRB THRB 3/4885THRA 4/4885
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands TSHR, THRA, THRB THRB 3/4885THRA 2/4885
US-20110098303-A1 Method of promoting nail growth using thyromimetic compounds TPO, POLR1C, TYR THRB 29/4885THRA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.